Fibrinogen during liver transplant
Part of Blood & lymphatic, Digestive system clinical trials.
This trial tests whether giving a clotting protein called fibrinogen helps control bleeding during a liver transplant from a deceased donor. It may be a good option if you have certain liver conditions or lower fibrinogen levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You need to be scheduled for a liver transplant from a deceased donor
- You should have one of these: low fibrinogen level, alcoholic cirrhosis, fatty liver disease (NASH), or hepatitis C
- You cannot have a living donor, a blood clotting disorder, an objection to blood transfusion, a severe allergy to plasma-based products, IgA deficiency with reaction to plasma, or liver/bile duct cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments to control bleeding during liver transplant surgery. One is a concentrated form of a clotting protein (fibrinogen concentrate) and the other is a blood product (cryoprecipitate). The goal is to find which works better to stop bleeding.
This trial studies how doctors manage bleeding before, during, and after liver transplant surgery. The goal is to improve safety and outcomes for people receiving a new liver.
This trial tests a personalized dose of fibrinogen, a protein that helps blood clot, for people having heart surgery with a heart-lung machine. The goal is to see if a tailored dose works better than a fixed dose after surgery.
This study looks at what happens when a drug called fibrinogen (which helps blood clot) is paid for by insurance during complex heart surgeries. It aims to see if having this drug covered changes how much blood is needed or how long you stay in the hospital.
This study is for people with severe liver cirrhosis who are getting a liver transplant from a living donor. It looks at the risk of bleeding or clotting problems after the transplant, to help doctors better manage these risks.
This study takes a small liver tissue sample (a liver biopsy) in men who previously received haemophilia gene therapy. The goal is to learn more about how the gene therapy works and how safe it is for the liver.
Hear when a new Liver Transplant Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.